ABL Launches New Website

ABL Launches New Website

  • November 14, 2011

Rockville, MD (November 14, 2011) – Advanced BioScience Laboratories, Inc. (ABL), a leading biomedical contract research and manufacturing organization, is pleased to announce the launch of a newly redesigned website at www.ablinc.com. The site incorporates ABL’s new logo, and details our expanded service offerings following the move to a state-of-the-art laboratory and manufacturing facility in Rockville, MD earlier this year.

The new website is designed to give our clients and partners improved access to information regarding ABL’s services and catalog products. The streamlined site structure and navigation ensures that all information is just one or two clicks away from the home page. In addition, ABL’s store front has a brand new look providing full details on our high quality reagents and kits. Features also include the latest ABL news, upcoming events and an extensive listing of staff publications.

ABL’s contract research capabilities for preclinical development include large and small animal models and expertise in efficacy, potency and immunogenicity testing. Contract manufacturing services include cGMP cell banking, protein therapeutics, and vaccine production capabilities carried out in dedicated cGMP suites for mammalian and microbial platforms.

We invite you to visit www.ablinc.com today, and come back often for the latest information on ABL’s clinical development solutions.

About ABL

Advanced BioScience Laboratories, Inc. (ABL) is a Maryland-based biomedical contract research and manufacturing organization dedicated to advancing vaccines, therapeutics and other biologic products. ABL has extensive experience working with diverse organizations, including various government and academic entities and commercial biopharmaceutical companies. Notable services include basic research, product design, process and assay development, preclinical in vivo models (including immunomonitoring), and Phase I/II cGMP biologics manufacturing. Since 2001 ABL has been a part of the Institut Mérieux, a group of four companies dedicated to developing translational science for better patient care globally. For more information on ABL and our services, please visit our website at www.ablinc.com.